Highlighted Article

 

Hepatitis C Virus Infection and Chemotherapy in Breast Cancer: A Retrospective Chart Analysis

Saptaparni Ghosh, et al., The Oncologist

Currently, there are no guidelines for chemotherapy administration in hepatitis C virus-positive patients with breast cancer. This article addresses the knowledge gap, comparing breast cancer patients with and without concurrent hepatitis C virus to determine level of tolerance to treatment.
 

 

 

ALK -Rearranged Non‐Small Cell Lung Cancer in 2020: Real-World Triumphs in an Era of Multigeneration ALK-Inhibitor Sequencing Informed by Drug Resistance Profiling

Malinda Itchins, et al., The Oncologist

This report underscores the importance of genetic analysis of serial biopsies to capture the dynamic therapeutic vulnerabilities within a patient’s tumor, while providing a perspective on the complexity of ALK tyrosine kinase inhibitor treatment sequencing.
 

 

 

Homologous Recombination Repair Defect May Predict Treatment Response to Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors

Mojun Zhu, et al., The Oncologist

This article describes a patient with high-grade pancreatic neuroendocrine tumor and BRCA1 germline mutation who had a significant response to Lutetium-177-Dotatate and summarizes the current state of clinical management of high-grade neuroendocrine tumors.
 

 

 

Taking the Longer View of COVID‐19

Bruce A. Chabner, MD Editor-in-Chief

What are the prospects for dealing with COVID‐19 more effectively in the future? This editorial addresses the question from the perspective of long‐term control of coronavirus infection.
 

 

 

Management of Cancer Patients During the COVID-19 Pandemic

Humaid O. Al‐Shamsi, et al., The Oncologist

Cancer patients have an increased risk of contracting COVID-19. This article addresses the challenges associated with managing cancer patients during the COVID-19 infection pandemic and suggests some practical approaches.